ELUT Quote, Financials, Valuation and Earnings

Technicals

Company Profile

Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. It operates through the following segments: Device Protection, Women’s Health, and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Cardiovascular segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Gaithersburg, MD.

Stock Forecast FAQ

In the current month, ELUT has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ELUT average analyst price target in the past 3 months is $5.00.

• Where Will Elutia, Inc. Stock Be In 1 Year?

  According to analysts, the consensus estimate is that Elutia, Inc. share price will rise to $5.00 per share over the next 12 months.

• What Do Analysts Say About Elutia, Inc.?

  Analysts are divided on their view about Elutia, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elutia, Inc. is a Sell and believe this share price will drop from its current level to $5.00.

• What Is Elutia, Inc.'s Price Target?

  The price target for Elutia, Inc. over the next 1-year time period is forecast to be $5.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

• Is ELUT A Buy, Sell Or Hold?

  According to Wall Street analysts, the consensus rating for Elutia, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

• How Can I Buy Shares Of ELUT?

  You can purchase shares of Elutia, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elutia, Inc. shares.

• What Is The Elutia, Inc. Share Price Today?

  Elutia, Inc. was last trading at $1.17 per share. This represents the most recent stock quote for Elutia, Inc.. Yesterday, Elutia, Inc. closed at $1.17 per share.

• How To Buy Elutia, Inc. Stock Online?

  In order to purchase Elutia, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

Related Companies

• Abbott Laboratories
• Accuray, Inc.
• Alphatec Holdings, Inc.
• Boston Scientific Corp.
• Plus Therapeutics, Inc.